Bertrand Bellier
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
Bertrand Bellier has a total of 216 co-authors. Here are the top co-authors by number of shared publications:
- David Klatzmann
Immunology, Immunopathology, Immunotherapy i3 Lab, INSERM UMRS-959, Sorbonne Université
32 shared publications - Véronique Thomas-Vaslin
UPMC University Paris 06, UMR7211, CNRS, UMR7211, INSERM, U959
20 shared publications David Klatzmann
Sorbonne Université, UMRS 959, laboratory I(3), F-75013 Paris, France; INSERM, UMRS 959, laboratory I(3), F-75013 Paris, France; AP-HP, Groupe Hospitalier Pitié-Salpêtrière, Department of Biotherapies and the Clinical Investigation Center in Biotherapy, F-75013 Paris, France
18 shared publications- Adrien Six
Immunology, Immunopathology, Immunotherapy i3 Lab, INSERM UMRS-959, Sorbonne Université
12 shared publications Adrien Six
UPMC University Paris 06, UMR7211, CNRS, UMR7211, INSERM, U959
6 shared publicationsChristophe Huret
Sorbonne Universités, UPMC Univ Paris 06, UMRS 959, Immunology, Immunopathology, Immunotherapy, Paris, France
6 shared publications
Latest Publications
- Open Access
- 6 May 2025
- Published by American Society for Clinical Investigation in JCI Insight
- Vol. 10 (12)
IL-1β signaling modulates T follicular helper and regulatory cells in human lymphoid tissues
Dysregulation of T follicular helper (Tfh) and T follicular regulatory (Tfr) cell homeostasis in germinal centers (GCs) can lead to antibody-mediated autoimmunity. While IL-1β modulates the GC response via IL-1R1 and IL-1R2 receptors on follicular T cells in animal models, its role in humans remains unclear. We analyzed Tfh and Tfr phenotypes in human secondary lymphoid organs (tonsils, spleen, and mesenteric lymph nodes) using flow cytometry, single-cell transcriptomics, and in vitro culture, comparing findings with samples from autoimmune patients. We observed organ-specific Tfh/Tfr phenotypes according to activation status and IL-1 receptor expression. An excess of IL-1R1 over IL-1R2 expression promoted a unique activated Tfr subset with Treg and GC-Tfh features. IL-1β signaling via IL-1R1 enhanced follicular T cell activation and Tfh-to-Tfr differentiation, while IL-1β inhibition upregulated IL-1R1, indicating a tightly regulated process. In autoimmune patients, high IL-1β and circulating Tfr levels correlated with increased autoantibody production, linking inflammation, IL-1β signaling, and Tfr/Tfh balance. Our findings highlight the critical role of IL-1β in follicular T cell activation and suggest that targeting IL-1β signaling in Tfh and Tfr cells could be a promising strategy for treating antibody-mediated autoimmune diseases.
- 6 May 2025
- Published by American Society for Clinical Investigation in JCI Insight
- Vol. 10 (12)
Open AccessIL-1β signaling modulates T follicular helper and regulatory cells in human lymphoid tissues
Dysregulation of T follicular helper (Tfh) and T follicular regulatory (Tfr) cell homeostasis in germinal centers (GCs) can lead to antibody-mediated autoimmunity. While IL-1β modulates the GC response via IL-1R1 and IL-1R2 receptors on follicular T cells in animal models, its role in humans remains unclear. We analyzed Tfh and Tfr phenotypes in human secondary lymphoid organs (tonsils, spleen, and mesenteric lymph nodes) using flow cytometry, single-cell transcriptomics, and in vitro culture, comparing findings with samples from autoimmune patients. We observed organ-specific Tfh/Tfr phenotypes according to activation status and IL-1 receptor expression. An excess of IL-1R1 over IL-1R2 expression promoted a unique activated Tfr subset with Treg and GC-Tfh features. IL-1β signaling via IL-1R1 enhanced follicular T cell activation and Tfh-to-Tfr differentiation, while IL-1β inhibition upregulated IL-1R1, indicating a tightly regulated process. In autoimmune patients, high IL-1β and circulating Tfr levels correlated with increased autoantibody production, linking inflammation, IL-1β signaling, and Tfr/Tfh balance. Our findings highlight the critical role of IL-1β in follicular T cell activation and suggest that targeting IL-1β signaling in Tfh and Tfr cells could be a promising strategy for treating antibody-mediated autoimmune diseases.
- Open Access
IL‐1R2 Expression in Tfr Cells Controls Allergic Anaphylaxis by Regulating IgG Versus IgE Responses
- Open Access
Low-dose interleukin-2 in birch pollen allergy: a phase-2 randomized double-blind placebo-controlled trial
S: Background: Regulatory T cells (Tregs) are pivotal in immune tolerance to allergens. Low-dose IL-2 (IL-2 LD ) expands and activates Tregs. We assessed IL-2 LD efficacy for controlling clinical responses to allergen exposures. Methods: RHINIL-2 was a phase-2a single-centre, randomised, double-blind, placebo-controlled proof-of-concept study. Twenty-four patients with allergic rhinitis to birch pollen (BP) were included, 66% having concomitant asthma. All had IgE and positive skin prick tests to BP at inclusion, and a total nasal symptom score (TNSS) ≥5 following a 4-hour nasal exposure to BP in an environmental-exposure-chamber (EEC). Patients received 1 MUI/day of IL-2 or Placebo for 5 days, followed by weekly injections for 4 weeks. Clinical responses to subsequent BP exposures in the EEC were evaluated using TNSS, the rhinitis visual analogue scale (VAS) and spirometry. The primary efficacy endpoint was the difference in TNSS area under the curve between inclusion and day 40 (TNSSΔAUC). This trial is registered with ClinicalTrials.gov ( NCT02424396 ). Outcomes: IL-2 LD treatment induced a significant expansion and activation of Tregs. The TNSSΔAUC in the ILT-101 and Placebo groups was non significantly different (-8.03 vs -4.76, p=0.32). TNSS and VAS AUCs were significantly reduced from baseline to day 40 in the ILT-101 group only (p=0.04 and p=0.01 respectively). The ratio of forced expiratory volume in 1 second / forced vital capacity (FEV 1P ) and the forced mid-expiratory flow (FEF 25-75% ) showed significant improvement in the ILT-101 vs Placebo groups at day 40 (p=0.04 and 0.04 respectively). There was a significant increase in eosinophils during treatment and no severe treatment-related adverse events. Interpretation: IL-2 LD is well-tolerated in allergic patients, including in those with asthma. Although there was a trend towards a reduction in nasal scores, the primary endpoint was not reached in this small study. However, the short treatment duration used in this study cannot have effects on IgE levels given their half-life. Thus the limited efficacy observed suggest that Tregs mitigate allergic reactions and represent novel targets for the treatment of allergy. Funding: Assistance Publique-Hôpitaux de Paris, ILTOO pharma, Agence Nationale de la Recherche Research in the context: Allergic rhinitis (AR) is a common inflammatory disorder of the nasal mucosa, affecting millions worldwide, and often associated with asthma. Its management encompasses various strategies targeting symptom relief, such as antihistamines, corticosteroids and leukotriene receptor antagonists. Biologics targeting specific pathways, such as IgE, IL-4, IL-5, and IL-13, are in development. Curative treatment such as allergen-specific immunotherapy (AIT) for re-establishing tolerance to the allergen have limited efficacy. Despites its often moderate severity, AR can profoundly affect the quality of life and remains an unmet medical need. Treg have a clear and direct role in preventing allergy, as exemplified by the fact that their complete deficiency in the IPEX syndrome leads to allergy. The role of Treg in mitigating an existing allergy is less clearly established. It mainly comes from the observation that successful allergen-specific immunotherapy (AIT) is associated with the induction of Tregs. Of note, both a Treg defect and a positive impact of Tregs during AIT have been described for allergic rhinitis patients. Collectively, these results highlight that strategies to increase Treg numbers and/or fitness might be beneficial in the treatment of allergic rhinitis. Evidence before this study: Treg-targeted therapies have not yet been evaluated in humans with allergy. That IL-2 LD has not yet been evaluated is possibly because it triggers eosinophilia. This is due to the stimulation of innate lymphoid cells type 2 (ILC2), which express the high affinity receptor for IL-2 and produce IL-5 upon IL-2 activation, which in turn triggers the eosinophilia. Eosinophils are critical mediators in allergic responses, contributing to inflammation and tissue damage. When exposed to allergens, eosinophils release molecules, including histamines, leukotrienes, and cytokines, which contribute to tissue inflammation and allergy symptoms. Eosinophils are particularly implicated in asthma and allergic rhinitis, in which they contribute to airway hyperresponsiveness, mucus production, and remodelling. IL-5 is a key cytokine for eosinophils and monoclonal antibodies against IL-5 are currently developed. Of note, the IL-2 LD -triggered IL-5-induced eosinophilia has not yet been associated with severe side effects, even in patients who have received daily IL-2 LD injections for years and had persistent eosinophilia. The added value of this study: This is to our knowledge the first study of a Treg-targeted therapy in allergy, and of IL-2LD in allergy. It shows that, as expected, IL-2LD can directly stimulate Tregs and indirectly eosinophils in patients with allergies. The eosinophilia went up to twice the normal value and had no clinical significance, including in patients with asthma. The IL-2LD safety profile in this double-blind placebo control study relieves the concerns of using it in allergy, and thus license its further clinical investigation, including in asthma. Although there was a trend towards a reduction in nasal scores, the primary endpoint was not reached in this small study. However, the short treatment duration used in this study cannot have effects on IgE levels given their half-life. Thus, the limited efficacy observed suggest that Tregs mitigate allergic reactions and represent novel targets for the treatment of allergy that warrants further clinical investigation in larger studies. Our study also highlights the value of EEC for studying a novel treatment of allergy. Implications of all the available evidence: The possible improvements in the clinical response to an allergen challenge were obtained after a short treatment that stimulated Treg fitness but could not have any effects on the effector mechanisms of allergy. Thus, as they showed that Treg could mitigate ongoing allergic response, Treg represents a novel target in allergy. This opens the door for combination therapies, notably with molecules targeting the effector immune responses and with allergen-specific therapies aimed at re-establishing tolerance to the allergen.
Open AccessLow-dose interleukin-2 in birch pollen allergy: a phase-2 randomized double-blind placebo-controlled trial
S: Background: Regulatory T cells (Tregs) are pivotal in immune tolerance to allergens. Low-dose IL-2 (IL-2 LD ) expands and activates Tregs. We assessed IL-2 LD efficacy for controlling clinical responses to allergen exposures. Methods: RHINIL-2 was a phase-2a single-centre, randomised, double-blind, placebo-controlled proof-of-concept study. Twenty-four patients with allergic rhinitis to birch pollen (BP) were included, 66% having concomitant asthma. All had IgE and positive skin prick tests to BP at inclusion, and a total nasal symptom score (TNSS) ≥5 following a 4-hour nasal exposure to BP in an environmental-exposure-chamber (EEC). Patients received 1 MUI/day of IL-2 or Placebo for 5 days, followed by weekly injections for 4 weeks. Clinical responses to subsequent BP exposures in the EEC were evaluated using TNSS, the rhinitis visual analogue scale (VAS) and spirometry. The primary efficacy endpoint was the difference in TNSS area under the curve between inclusion and day 40 (TNSSΔAUC). This trial is registered with ClinicalTrials.gov ( NCT02424396 ). Outcomes: IL-2 LD treatment induced a significant expansion and activation of Tregs. The TNSSΔAUC in the ILT-101 and Placebo groups was non significantly different (-8.03 vs -4.76, p=0.32). TNSS and VAS AUCs were significantly reduced from baseline to day 40 in the ILT-101 group only (p=0.04 and p=0.01 respectively). The ratio of forced expiratory volume in 1 second / forced vital capacity (FEV 1P ) and the forced mid-expiratory flow (FEF 25-75% ) showed significant improvement in the ILT-101 vs Placebo groups at day 40 (p=0.04 and 0.04 respectively). There was a significant increase in eosinophils during treatment and no severe treatment-related adverse events. Interpretation: IL-2 LD is well-tolerated in allergic patients, including in those with asthma. Although there was a trend towards a reduction in nasal scores, the primary endpoint was not reached in this small study. However, the short treatment duration used in this study cannot have effects on IgE levels given their half-life. Thus the limited efficacy observed suggest that Tregs mitigate allergic reactions and represent novel targets for the treatment of allergy. Funding: Assistance Publique-Hôpitaux de Paris, ILTOO pharma, Agence Nationale de la Recherche Research in the context: Allergic rhinitis (AR) is a common inflammatory disorder of the nasal mucosa, affecting millions worldwide, and often associated with asthma. Its management encompasses various strategies targeting symptom relief, such as antihistamines, corticosteroids and leukotriene receptor antagonists. Biologics targeting specific pathways, such as IgE, IL-4, IL-5, and IL-13, are in development. Curative treatment such as allergen-specific immunotherapy (AIT) for re-establishing tolerance to the allergen have limited efficacy. Despites its often moderate severity, AR can profoundly affect the quality of life and remains an unmet medical need. Treg have a clear and direct role in preventing allergy, as exemplified by the fact that their complete deficiency in the IPEX syndrome leads to allergy. The role of Treg in mitigating an existing allergy is less clearly established. It mainly comes from the observation that successful allergen-specific immunotherapy (AIT) is associated with the induction of Tregs. Of note, both a Treg defect and a positive impact of Tregs during AIT have been described for allergic rhinitis patients. Collectively, these results highlight that strategies to increase Treg numbers and/or fitness might be beneficial in the treatment of allergic rhinitis. Evidence before this study: Treg-targeted therapies have not yet been evaluated in humans with allergy. That IL-2 LD has not yet been evaluated is possibly because it triggers eosinophilia. This is due to the stimulation of innate lymphoid cells type 2 (ILC2), which express the high affinity receptor for IL-2 and produce IL-5 upon IL-2 activation, which in turn triggers the eosinophilia. Eosinophils are critical mediators in allergic responses, contributing to inflammation and tissue damage. When exposed to allergens, eosinophils release molecules, including histamines, leukotrienes, and cytokines, which contribute to tissue inflammation and allergy symptoms. Eosinophils are particularly implicated in asthma and allergic rhinitis, in which they contribute to airway hyperresponsiveness, mucus production, and remodelling. IL-5 is a key cytokine for eosinophils and monoclonal antibodies against IL-5 are currently developed. Of note, the IL-2 LD -triggered IL-5-induced eosinophilia has not yet been associated with severe side effects, even in patients who have received daily IL-2 LD injections for years and had persistent eosinophilia. The added value of this study: This is to our knowledge the first study of a Treg-targeted therapy in allergy, and of IL-2LD in allergy. It shows that, as expected, IL-2LD can directly stimulate Tregs and indirectly eosinophils in patients with allergies. The eosinophilia went up to twice the normal value and had no clinical significance, including in patients with asthma. The IL-2LD safety profile in this double-blind placebo control study relieves the concerns of using it in allergy, and thus license its further clinical investigation, including in asthma. Although there was a trend towards a reduction in nasal scores, the primary endpoint was not reached in this small study. However, the short treatment duration used in this study cannot have effects on IgE levels given their half-life. Thus, the limited efficacy observed suggest that Tregs mitigate allergic reactions and represent novel targets for the treatment of allergy that warrants further clinical investigation in larger studies. Our study also highlights the value of EEC for studying a novel treatment of allergy. Implications of all the available evidence: The possible improvements in the clinical response to an allergen challenge were obtained after a short treatment that stimulated Treg fitness but could not have any effects on the effector mechanisms of allergy. Thus, as they showed that Treg could mitigate ongoing allergic response, Treg represents a novel target in allergy. This opens the door for combination therapies, notably with molecules targeting the effector immune responses and with allergen-specific therapies aimed at re-establishing tolerance to the allergen.
- Open Access
- 25 August 2023
- Published by Elsevier in European Journal of Pharmaceutics and Biopharmaceutics
- Vol. 191, 124-138
Particulate antigens administrated by intranasal and intravaginal routes in a prime-boost strategy improve HIV-specific TFH generation, high-quality antibodies and long-lasting mucosal immunity
- 25 August 2023
- Published by Elsevier in European Journal of Pharmaceutics and Biopharmaceutics
- Vol. 191, 124-138
Open AccessParticulate antigens administrated by intranasal and intravaginal routes in a prime-boost strategy improve HIV-specific TFH generation, high-quality antibodies and long-lasting mucosal immunity
- Open Access
Interleukin-1 regulates follicular T cells during the germinal center reaction
Antibody production by plasma cells and generation of long-term memory B-cells are positively regulated by Tfh cells and negatively regulated by Tfr cells in germinal centers. However, the precise role of Tfr cells in controlling antibody production is still unclear. We have previously shown that Tfh and Tfr cells both express IL-1R1, while only Tfr cells express the IL-1R2 decoy and IL-1Ra antagonist receptors. To study the role of these receptors in the regulation of the B cell response by Tfh and/or Tfr cells, we generated mice with knockout of IL-1 receptors in Tfh and/or Tfr cells and measured antibody production and cell activation upon immunization. We showed that IL-1β concentration is increased in the draining lymph node after immunization. Antigen-specific antibody levels and cell activation phenotypes indicated that IL-1β can activate both Tfh and Tfr cells through IL-1R1 stimulation. Surprisingly, IL-1R2 and IL-1Ra expression on Tfr cells does not block IL-1 activation of Tfh cells, but rather prevents IL-1/IL-1R1-mediated early activation of Tfr cells. IL-1Rs similarly regulate antibody response against autoantigens and its related pathophysiology in an experimental lupus model. Altogether, these results show that IL-1R1 inhibitory receptors expressed by Tfr cells prevent their own activation and suppressive function, thus licensing IL-1-mediated activation of Tfh cells after immunization. One Sentence Summary Functional knockout of IL-1 agonist (R1) and antagonist (R2 and Ra) receptors reveals that IL-1-R2 and -Ra on Tfr cells prevent their own early activation to license the expansion and activation of Tfh cells after immunization.
Open AccessInterleukin-1 regulates follicular T cells during the germinal center reaction
Antibody production by plasma cells and generation of long-term memory B-cells are positively regulated by Tfh cells and negatively regulated by Tfr cells in germinal centers. However, the precise role of Tfr cells in controlling antibody production is still unclear. We have previously shown that Tfh and Tfr cells both express IL-1R1, while only Tfr cells express the IL-1R2 decoy and IL-1Ra antagonist receptors. To study the role of these receptors in the regulation of the B cell response by Tfh and/or Tfr cells, we generated mice with knockout of IL-1 receptors in Tfh and/or Tfr cells and measured antibody production and cell activation upon immunization. We showed that IL-1β concentration is increased in the draining lymph node after immunization. Antigen-specific antibody levels and cell activation phenotypes indicated that IL-1β can activate both Tfh and Tfr cells through IL-1R1 stimulation. Surprisingly, IL-1R2 and IL-1Ra expression on Tfr cells does not block IL-1 activation of Tfh cells, but rather prevents IL-1/IL-1R1-mediated early activation of Tfr cells. IL-1Rs similarly regulate antibody response against autoantigens and its related pathophysiology in an experimental lupus model. Altogether, these results show that IL-1R1 inhibitory receptors expressed by Tfr cells prevent their own activation and suppressive function, thus licensing IL-1-mediated activation of Tfh cells after immunization. One Sentence Summary Functional knockout of IL-1 agonist (R1) and antagonist (R2 and Ra) receptors reveals that IL-1-R2 and -Ra on Tfr cells prevent their own early activation to license the expansion and activation of Tfh cells after immunization.
- Open Access
- 1 November 2017
- Published by American Society for Microbiology in Journal of Virology
- Vol. 91 (21) , e01230-17
Retrovirus-Based Virus-Like Particle Immunogenicity and Its Modulation by Toll-Like Receptor Activation
Retrovirus-derived virus-like particles (VLPs) are particularly interesting vaccine platforms, as they trigger efficient humoral and cellular immune responses and can be used to display heterologous antigens. In this study, we characterized the intrinsic immunogenicity of VLPs and investigated their possible adjuvantization by incorporation of Toll-like receptor (TLR) ligands. We designed a noncoding single-stranded RNA (ncRNA) that could be encapsidated by VLPs and induce TLR7/8 signaling. We found that VLPs efficiently induce in vitro dendritic cell activation, which can be improved by ncRNA encapsidation ( ncRNA VLPs). Transcriptome studies of dendritic cells harvested from the spleens of immunized mice identified antigen presentation and immune activation as the main gene expression signatures induced by VLPs, while TLR signaling and Th1 signatures characterize ncRNA VLPs. In vivo and compared with standard VLPs, ncRNA VLPs promoted Th1 responses and improved CD8 + T cell proliferation in a MyD88-dependent manner. In an HIV vaccine mouse model, HIV-pseudotyped ncRNA VLPs elicited stronger antigen-specific cellular and humoral responses than VLPs. Altogether, our findings provide molecular evidence for a strong vaccine potential of retrovirus-derived VLPs that can be further improved by harnessing TLR-mediated immune activation. IMPORTANCE We previously reported that DNA vaccines encoding antigens displayed in/on retroviral VLPs are more efficient than standard DNA vaccines at inducing cellular and humoral immune responses. We aimed to decipher the mechanisms and investigated the VLPs' immunogenicity independently of DNA vaccination. We show that VLPs have the ability to activate antigen-presenting cells directly, thus confirming their intrinsic immunostimulatory properties and their potential to be used as an antigenic platform. Notably, this immunogenicity can be further improved and/or oriented by the incorporation into VLPs of ncRNA, which provides further TLR-mediated activation and Th1-type CD4 + and CD8 + T cell response orientation. Our results highlight the versatility of retrovirus-derived VLP design and the value of using ncRNA as an intrinsic vaccine adjuvant.
- 1 November 2017
- Published by American Society for Microbiology in Journal of Virology
- Vol. 91 (21) , e01230-17
Open AccessRetrovirus-Based Virus-Like Particle Immunogenicity and Its Modulation by Toll-Like Receptor Activation
Retrovirus-derived virus-like particles (VLPs) are particularly interesting vaccine platforms, as they trigger efficient humoral and cellular immune responses and can be used to display heterologous antigens. In this study, we characterized the intrinsic immunogenicity of VLPs and investigated their possible adjuvantization by incorporation of Toll-like receptor (TLR) ligands. We designed a noncoding single-stranded RNA (ncRNA) that could be encapsidated by VLPs and induce TLR7/8 signaling. We found that VLPs efficiently induce in vitro dendritic cell activation, which can be improved by ncRNA encapsidation ( ncRNA VLPs). Transcriptome studies of dendritic cells harvested from the spleens of immunized mice identified antigen presentation and immune activation as the main gene expression signatures induced by VLPs, while TLR signaling and Th1 signatures characterize ncRNA VLPs. In vivo and compared with standard VLPs, ncRNA VLPs promoted Th1 responses and improved CD8 + T cell proliferation in a MyD88-dependent manner. In an HIV vaccine mouse model, HIV-pseudotyped ncRNA VLPs elicited stronger antigen-specific cellular and humoral responses than VLPs. Altogether, our findings provide molecular evidence for a strong vaccine potential of retrovirus-derived VLPs that can be further improved by harnessing TLR-mediated immune activation. IMPORTANCE We previously reported that DNA vaccines encoding antigens displayed in/on retroviral VLPs are more efficient than standard DNA vaccines at inducing cellular and humoral immune responses. We aimed to decipher the mechanisms and investigated the VLPs' immunogenicity independently of DNA vaccination. We show that VLPs have the ability to activate antigen-presenting cells directly, thus confirming their intrinsic immunostimulatory properties and their potential to be used as an antigenic platform. Notably, this immunogenicity can be further improved and/or oriented by the incorporation into VLPs of ncRNA, which provides further TLR-mediated activation and Th1-type CD4 + and CD8 + T cell response orientation. Our results highlight the versatility of retrovirus-derived VLP design and the value of using ncRNA as an intrinsic vaccine adjuvant.
- 1 June 2017
- Published by Elsevier in Gastroenterology
- Vol. 152 (8) , 2052-2062.e2
Direct-Acting Antiviral Therapy Restores Immune Tolerance to Patients With Hepatitis C Virus–Induced Cryoglobulinemia Vasculitis
- 1 June 2017
- Published by Elsevier in Gastroenterology
- Vol. 152 (8) , 2052-2062.e2
Direct-Acting Antiviral Therapy Restores Immune Tolerance to Patients With Hepatitis C Virus–Induced Cryoglobulinemia Vasculitis
- Open Access
- 1 May 2017
- Published by Elsevier in Mucosal Immunology
- Vol. 10 (3) , 695-704
The regulatory dendritic cell marker C1q is a potent inhibitor of allergic inflammation
- 1 May 2017
- Published by Elsevier in Mucosal Immunology
- Vol. 10 (3) , 695-704
Open AccessThe regulatory dendritic cell marker C1q is a potent inhibitor of allergic inflammation
- Open Access
- 1 July 2016
- Published by Oxford University Press (OUP) in The Journal of Immunology
- Vol. 197 (1) , 188-198
Low-Dose IL-2 Induces Regulatory T Cell–Mediated Control of Experimental Food Allergy
Regulatory T cells (Tregs) are pivotal for maintenance of immune self-tolerance and also regulate immune responses to exogenous Ags, including allergens. Both decreased Treg number and function have been reported in allergic patients, offering new therapeutic perspectives. We previously demonstrated that Tregs can be selectively expanded and activated by low doses of IL-2 (ld-IL-2) inducing immunoregulation without immunosuppression and established its protective effect in autoimmune diseases. In this study, we evaluated the ability of ld-IL-2 to control allergy in an experimental model of food allergy. Ld-IL-2 induced Treg expansion and activation that elicited protection against clinical manifestations of food allergy in two mouse models with OVA and peanut. This clinical effect was lost in Treg-depleted mice, demonstrating the major contribution of Tregs in ld-IL-2 efficacy. Mechanistic studies further indicated that protection from allergy could be explained by a Treg-dependent local modification of the Th1/Th2 balance and an inhibition of mast cell recruitment and activation. Preventive and therapeutic effects of ld-IL-2 were observed over a 7-mo-period, highlighting its long-term efficacy. This study demonstrated that ld-IL-2 is efficient to prevent and to treat allergic immune responses, and thus represents a promising therapeutic strategy for managing allergic diseases.
- 1 July 2016
- Published by Oxford University Press (OUP) in The Journal of Immunology
- Vol. 197 (1) , 188-198
Open AccessLow-Dose IL-2 Induces Regulatory T Cell–Mediated Control of Experimental Food Allergy
Regulatory T cells (Tregs) are pivotal for maintenance of immune self-tolerance and also regulate immune responses to exogenous Ags, including allergens. Both decreased Treg number and function have been reported in allergic patients, offering new therapeutic perspectives. We previously demonstrated that Tregs can be selectively expanded and activated by low doses of IL-2 (ld-IL-2) inducing immunoregulation without immunosuppression and established its protective effect in autoimmune diseases. In this study, we evaluated the ability of ld-IL-2 to control allergy in an experimental model of food allergy. Ld-IL-2 induced Treg expansion and activation that elicited protection against clinical manifestations of food allergy in two mouse models with OVA and peanut. This clinical effect was lost in Treg-depleted mice, demonstrating the major contribution of Tregs in ld-IL-2 efficacy. Mechanistic studies further indicated that protection from allergy could be explained by a Treg-dependent local modification of the Th1/Th2 balance and an inhibition of mast cell recruitment and activation. Preventive and therapeutic effects of ld-IL-2 were observed over a 7-mo-period, highlighting its long-term efficacy. This study demonstrated that ld-IL-2 is efficient to prevent and to treat allergic immune responses, and thus represents a promising therapeutic strategy for managing allergic diseases.
- Open Access
- 27 June 2016
- Published by Taylor & Francis in OncoImmunology
- Vol. 5 (7) , e1164363
Intra-cheek immunization as a novel vaccination route for therapeutic vaccines of head and neck squamous cell carcinomas using plasmo virus-like particles
Despite current therapy, head and neck squamous cell carcinomas (HNSCCs) arising from various mucosal sites of the upper aero-digestive tract frequently relapse in a loco-regional manner and have a poor prognosis. Our objective was to validate an innovative mucosal route of vaccination using plasmo virus-like particles (pVLPs) in a pre-clinical orthotopic model of HNSCCs. For this purpose, we used pVLP-E7, that are plasmid DNA encoding retroviral virus-like particles carrying a truncated E7 oncoprotein from HPV-16 as antigen model, to vaccinate mice bearing pre-established TC-1 tumors implanted into the buccal mucosa. pVLP-E7 were combined with clinical grade TLR agonists (Imiquimod and CpG-ODN). In this pre-clinical orthotopic model, whose tumor microenvironment resembles to those of human HNSCCs, different mucosal vaccination routes were tested for their ability to elicit efficient immune and antitumoral responses. Results showed that mucosal intra-cheek (IC) vaccinations using pVLP-E7, comparatively to intradermic vaccinations (ID), gave rise to higher mobilization of mucosal (CD49a+) CD8+ specific effector T cells in both tumor draining lymph nodes (TdLNs) and tumor microenvironment resulting in better antitumor effects and in a long-term protection against tumor rechallenge. In vivo CD8+ depletion demonstrated that antitumoral effects were fully dependent upon the presence of CD8+ T cells. Validation of IC mucosal vaccinations with pVLPs combined with adjuvants using a pre-clinical orthotopic model of HNSCC provides valuable pre-clinical data to rapidly envision the use of such therapeutic vaccines in patients with HNSCCs, inasmuch as vaccinal components and adjuvants can be easily obtained as clinical grade reagents.
- 27 June 2016
- Published by Taylor & Francis in OncoImmunology
- Vol. 5 (7) , e1164363
Open AccessIntra-cheek immunization as a novel vaccination route for therapeutic vaccines of head and neck squamous cell carcinomas using plasmo virus-like particles
Despite current therapy, head and neck squamous cell carcinomas (HNSCCs) arising from various mucosal sites of the upper aero-digestive tract frequently relapse in a loco-regional manner and have a poor prognosis. Our objective was to validate an innovative mucosal route of vaccination using plasmo virus-like particles (pVLPs) in a pre-clinical orthotopic model of HNSCCs. For this purpose, we used pVLP-E7, that are plasmid DNA encoding retroviral virus-like particles carrying a truncated E7 oncoprotein from HPV-16 as antigen model, to vaccinate mice bearing pre-established TC-1 tumors implanted into the buccal mucosa. pVLP-E7 were combined with clinical grade TLR agonists (Imiquimod and CpG-ODN). In this pre-clinical orthotopic model, whose tumor microenvironment resembles to those of human HNSCCs, different mucosal vaccination routes were tested for their ability to elicit efficient immune and antitumoral responses. Results showed that mucosal intra-cheek (IC) vaccinations using pVLP-E7, comparatively to intradermic vaccinations (ID), gave rise to higher mobilization of mucosal (CD49a+) CD8+ specific effector T cells in both tumor draining lymph nodes (TdLNs) and tumor microenvironment resulting in better antitumor effects and in a long-term protection against tumor rechallenge. In vivo CD8+ depletion demonstrated that antitumoral effects were fully dependent upon the presence of CD8+ T cells. Validation of IC mucosal vaccinations with pVLPs combined with adjuvants using a pre-clinical orthotopic model of HNSCC provides valuable pre-clinical data to rapidly envision the use of such therapeutic vaccines in patients with HNSCCs, inasmuch as vaccinal components and adjuvants can be easily obtained as clinical grade reagents.